Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB
ChemBioChem · 2024
DOI: 10.1002/cbic.202400081 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Juan Camilo Losada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Cra. 7 No. 43-82 Building 54, Lab 305 A…. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III, Acetylglucosaminidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pontificia Universidad Javeriana, National MPS Society, Institute for the Study of Inborn Errors of Metabolism (Pontificia Universidad Javeriana.
Abstract (Originalsprache)
Mucopolysaccharidosis type IIIB (MPS IIIB) is an autosomal inherited disease caused by mutations in gene encoding the lysosomal enzyme N−acetyl‐alpha‐glucosaminidase (NAGLU). These mutations result in reduced NAGLU activity, preventing it from catalyzing the hydrolysis of the glycosaminoglycan heparan sulfate (HS). There are currently no approved treatments for MPS IIIB. A novel approach in the treatment of lysosomal storage diseases is the use of pharmacological chaperones (PC). In this study, we used a drug repurposing approach to identify and characterize novel potential PCs for NAGLU enzyme. We modeled the interaction of natural and artificial substrates within the active cavity of NAGLU (orthosteric site) and predicted potential allosteric sites. We performed a virtual screening for both the orthosteric and the predicted allosteric site against a curated database of human tested molecules. Considering the binding affinity and predicted blood‐brain barrier permeability and gastrointestinal absorption, we selected atovaquone and piperaquine as orthosteric and allosteric PCs. The PCs were evaluated by their capacity to bind NAGLU and the ability to restore the enzymatic activity in human MPS IIIB fibroblasts These results represent novel PCs described for MPS IIIB and demonstrate the potential to develop novel therapeutic alternatives for this and other protein deficiency diseases
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Cra. 7 No. 43-82 Building 54, Lab 305 A., Bogotá D.C., 110231, Colombia.
- Chemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Cra. 7 No. 43-82 Building 52, Room 110 305 A., Bogotá D.C., 110231, Colombia.
- Dogma Biotech, Cr 13 A No. 127 A-84, Bogotá D.C., 110111, Colombia.
ORCID-Profile: Alexander Rodríguez-López, Angela Johana Espejo-Mojica
Förderung
- Pontificia Universidad Javeriana
- National MPS Society
- Institute for the Study of Inborn Errors of Metabolism (Pontificia Universidad Javeriana
Zitieren
APA
Losada, J. C., Triana, H., Vanegas, E., Caro, A., Rodríguez-López, A., Espejo-Mojica, A. J., & Alméciga-Diaz, C. J. (2024). Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB. ChemBioChem. https://doi.org/10.1002/cbic.202400081
Vancouver
Losada JC, Triana H, Vanegas E, Caro A, Rodríguez-López A, Espejo-Mojica AJ, et al. Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB. ChemBioChem. 2024. doi:10.1002/cbic.202400081
BibTeX
@article{Losada2024,
author = {Losada, Juan Camilo and Triana, Heidy and Vanegas, Egdda and Caro, Angela and Rodríguez-López, Alexander and Espejo-Mojica, Angela Johana and Alméciga-Diaz, Carlos Javier},
title = {Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB},
journal = {ChemBioChem},
year = {2024},
doi = {10.1002/cbic.202400081}
}
EUVIMED